BioSpace News Archive

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2019, following the close of market on Wednesday, December 11, 2019.

Technavio has announced its latest market research report titled global dental laboratories market 2020-2024

This location has allowed for the opportunity to grow the NaBITA team, and the association is pleased to announce the following new appointments

Carestream’s Dual-Energy technology has been approved for chest X-rays on its DRX-Evolution Plus System.

The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first subjects in a Phase I Drug-Drug Interaction (DDI) study, SLS-002-101.

EIZO Inc. announced today the release of the RadiForce RX1270, a 30.9-inch, super-high-resolution 12-megapixel color monitor ideal for multi-modality medical applications.

CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the release of the company’s inaugural Healthcare CIO Factbook.

Aesthetic Medical International Holdings Group Limited (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced that the Company has redeemed an outstanding convertible note on November 14, 2019.

The Phase 1 trial aims to evaluate safety, tolerability and initial anti-tumor activity of IV SB 11285 in patients with advanced solid tumors.